Remove Ablation Remove Arrhythmia Remove Defibrillator
article thumbnail

Preventive ablation of ventricular tachycardia avoids shocks and hospitalization, finds clinical trial

Medical Xpress - Cardiology

The first randomized trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular arrhythmias (VAs) reduces the risk of appropriate implantable cardioverter-defibrillator (ICD) therapy and unplanned hospitalization in patients with no (..)

article thumbnail

Ablation of Ventricular Tachycardia in Patients with ischemic cardiomyopathy and without an ICD – For the times they are a-changin´?

HeartRhythm

Recent advancements in catheter ablation for structural ventricular tachycardia (VT), such as high-density mapping and cardiac imaging-based detection of target areas, have significantly improved the efficacy of ablation procedures.

article thumbnail

PO-01-133 ACTIVE ARRHYTHMIA PATTERN: A NOVEL PREDICTOR OF ICD SHOCKS AND MAJOR CARDIOVASCULAR EVENTS. A SUB ANALYSIS FROM THE PARTITA STUDY

HeartRhythm

In the PARTITA trial antitachycardia pacing (ATP) predicted the occurrence of implantable cardioverter-defibrillator (ICD) shocks. Catheter ablation of ventricular tachycardia after the first shock reduced the risk of death or worsening heart failure (wHF).

article thumbnail

Ventricular Tachycardia Management

All About Cardiovascular System and Disorders

Ventricular tachycardia is a potentially life threatening cardiac arrhythmia. Chronic recurrent monomorphic VT like fascicular tachycardia and right ventricular outflow tract tachycardia are also amenable to electrophysiological mapping and ablation. If the rate is very fast, hemodynamic deterioration can occur rapidly.

article thumbnail

Stereotactic Body Radiotherapy for Refractory Ventricular Tachycardia Still paving the road to randomized trials.

HeartRhythm

Sudden cardiac death remains the main killer of adults in industrialized countries and reentrant ventricular arrhythmia (VA) is its main underlying mechanism1.

article thumbnail

Management of arrhythmogenic right ventricular cardiomyopathy

Heart BMJ

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. Emerging evidence suggests that combining flecainide and bisoprolol may be efficacious.

article thumbnail

Exploring Potential New Treatment for Ventricular Tachycardia

DAIC

They include medications that are not very effective and cause unpleasant side effects, an implantable cardioverter-defibrillator (or ICD) that provides an internal shock to correct the heartbeat, and a procedure called catheter ablation. Unfortunately, ablation also destroys healthy heart tissue in the process.